Department of Pharmacology and Pharmaceutical Chemistry, Medical Faculty, Shevchenko Transnistria State University, Tiraspol, Moldova.
Department of Chemical Synthesis, Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation, Moscow, Russia.
SAR QSAR Environ Res. 2024 Jun;35(6):505-530. doi: 10.1080/1062936X.2024.2371155. Epub 2024 Jul 15.
Histone deacetylase 6 (HDAC6) is a promising drug target for the treatment of human diseases such as cancer, neurodegenerative diseases (in particular, Alzheimer's disease), and multiple sclerosis. Considerable attention is paid to the development of selective non-toxic HDAC6 inhibitors. To this end, we successfully form a set of 3854 compounds and proposed adequate regression QSAR models for HDAC6 inhibitors. The models have been developed using the PubChem, Klekota-Roth, 2D atom pair fingerprints, and RDkit descriptors and the gradient boosting, support vector machines, neural network, and k-nearest neighbours methods. The models are integrated into the developed HT_PREDICT application, which is freely available at https://htpredict.streamlit.app/. In vitro studies have confirmed the predictive ability of the proposed QSAR models integrated into the HT_PREDICT web application. In addition, the virtual screening performed with the HT_PREDICT web application allowed us to propose two promising inhibitors for further investigations.
组蛋白去乙酰化酶 6(HDAC6)是治疗人类疾病(如癌症、神经退行性疾病(尤其是阿尔茨海默病)和多发性硬化症)的有前途的药物靶点。人们对选择性无毒 HDAC6 抑制剂的开发给予了相当大的关注。为此,我们成功地构建了一组 3854 个化合物,并提出了用于 HDAC6 抑制剂的充分回归 QSAR 模型。这些模型是使用 PubChem、Klekota-Roth、2D 原子对指纹和 RDkit 描述符以及梯度提升、支持向量机、神经网络和 k-最近邻方法开发的。这些模型已集成到开发的 HT_PREDICT 应用程序中,该应用程序可在 https://htpredict.streamlit.app/ 上免费获得。体外研究证实了集成到 HT_PREDICT 网络应用程序中的拟议 QSAR 模型的预测能力。此外,使用 HT_PREDICT 网络应用程序进行的虚拟筛选使我们能够提出两种有前途的抑制剂进行进一步研究。